uniQure (NASDAQ:QURE) Stock Price Passes Below 200-Day Moving Average of $6.06

Shares of uniQure (NASDAQ:QURE) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $6.06 and traded as low as $4.66. uniQure shares last traded at $4.71, with a volume of 440,845 shares changing hands.

Analysts Set New Price Targets

A number of analysts have recently commented on the stock. StockNews.com upgraded shares of uniQure to a “sell” rating in a report on Friday, March 1st. The Goldman Sachs Group cut shares of uniQure from a “buy” rating to a “neutral” rating and dropped their target price for the company from $63.00 to $8.00 in a report on Thursday, February 29th. Mizuho lowered their price target on uniQure from $10.00 to $7.00 and set a “neutral” rating for the company in a research report on Monday, March 4th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $28.00 price target on shares of uniQure in a research report on Tuesday, January 16th. Finally, HC Wainwright lowered their price target on uniQure from $30.00 to $25.00 and set a “buy” rating for the company in a research report on Friday, March 1st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $32.00.

uniQure Trading Down 0.8 %

The stock has a 50-day simple moving average of $5.36 and a two-hundred day simple moving average of $6.05. The company has a debt-to-equity ratio of 0.49, a quick ratio of 8.68 and a current ratio of 8.85. The firm has a market cap of $223.41 million, a PE ratio of -0.72 and a beta of 0.95.

uniQure (NASDAQ:QURE) last issued its earnings results on Wednesday, February 28th. The biotechnology company reported ($1.53) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.54) by $0.01. uniQure had a negative return on equity of 99.31% and a negative net margin of 1,947.09%. The business had revenue of $6.69 million during the quarter, compared to analyst estimates of $3.20 million. As a group, sell-side analysts anticipate that uniQure will post -4.49 EPS for the current year.

Insiders Place Their Bets

In other uniQure news, CEO Matthew C. Kapusta sold 27,904 shares of the business’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $6.35, for a total value of $177,190.40. Following the completion of the transaction, the chief executive officer now owns 440,839 shares of the company’s stock, valued at approximately $2,799,327.65. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, COO Pierre Caloz sold 9,455 shares of the company’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $6.47, for a total transaction of $61,173.85. Following the completion of the sale, the chief operating officer now owns 85,643 shares of the company’s stock, valued at approximately $554,110.21. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Matthew C. Kapusta sold 27,904 shares of the company’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $6.35, for a total transaction of $177,190.40. Following the sale, the chief executive officer now directly owns 440,839 shares of the company’s stock, valued at approximately $2,799,327.65. The disclosure for this sale can be found here. In the last 90 days, insiders sold 53,265 shares of company stock valued at $339,845. 4.05% of the stock is owned by insiders.

Institutional Investors Weigh In On uniQure

Several hedge funds and other institutional investors have recently made changes to their positions in QURE. PNC Financial Services Group Inc. increased its position in shares of uniQure by 152.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,038 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 1,231 shares during the last quarter. Bank of Montreal Can grew its stake in shares of uniQure by 104.4% during the 1st quarter. Bank of Montreal Can now owns 20,249 shares of the biotechnology company’s stock valued at $363,000 after acquiring an additional 10,341 shares during the period. Rhumbline Advisers increased its holdings in uniQure by 19.1% in the 1st quarter. Rhumbline Advisers now owns 29,860 shares of the biotechnology company’s stock worth $540,000 after acquiring an additional 4,779 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its holdings in uniQure by 14.1% in the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 31,076 shares of the biotechnology company’s stock worth $562,000 after acquiring an additional 3,839 shares in the last quarter. Finally, BlackRock Inc. increased its holdings in uniQure by 1.7% in the 1st quarter. BlackRock Inc. now owns 4,366,736 shares of the biotechnology company’s stock worth $78,908,000 after acquiring an additional 72,931 shares in the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.